

07 - 06 - 01 HOLLANDER LAW FIRM, P.L.

INTELLECTUAL PROPERTY LAW
SUITE 305

10300 EATON PLACE FAIRFAX, VIRGINIA 22030

TELEPHONE: 703-383-4800 FAX: 703-383-4804 EMAIL: hollander.law@prodigy.net IRINA S. ZEMEL (D.C., MD and NJ bars only)

1036 U.S. PTO 09/899863 09/05/01

Express Mail Certificate

Date TULY 5, 2001 Label No. EX 265 208 994 U.S

I hereby certify that, on the date indicated above, I deposited this paper and accompanying papers and fee with the U. S. Postal Service and that it was addressed to the Assistant Commissioner for Patents, Washington, D. C. 20231, by "Express Mail Post Office To Addressee" service.

PHYLLIS D. CALBUGLE Name (Print)

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: NZK-128-1 Prior Application: 09/333,521

Prior Art Unit: 1648

Prior Examiner: Winkler, U.

Assistant Commissioner For Patents Washington, DC 20231

Sir:

This is a request for filing the enclosed divisional application under 37 C.F.R. Section 1.53(b), of pending prior application Serial No. 09/333,521, filed on June 15, 1999, in the name of Yoichi FUJII et al. for NEF-ATTACHABLE PROTEIN, DNA ENCODING THE PROTEIN AND A MONOCLONAL ANTIBODY AGAINST SAID PROTEIN. The enclosed divisional application includes 19 pages of specification, 4 pages of claims, 1 page of abstract, and one (1) sheet of corrected formal drawings as filed in parent application Serial No. 09/333,521, filed June 15, 1999. Also enclosed are three (3) pages of a paper copy of the compliant Sequence Listing filed via certificate of

Y. FUJII et al. Rule 1.53 Divisional of 09/333,521 NZK-128-1

mailing on December 20, 1999 with a Preliminary Amendment and Compliance With Sequence Rules 1.821-1.825 in parent application Serial No. 09/333,521. Please see the request to use the compliant "Sequence Listing", at page 3, below. Further, enclosed is a copy of the executed Declaration from the prior application.

This transmittal letter is submitted in triplicate.

Before calculating the filing fee, please cancel claims: 4-8

A Preliminary Amendment is enclosed.

An Information Disclosure Statement is being filed concurrently herewith.

The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION LESS ANY CLAIMS

CANCELLED BY AMENDMENT ABOVE

Basic filing fee		\$	710.00
Total extra claims (3) x \$18.00		\$	54.00
Independent claims over $3 = ($	x \$80.00	<u>\$</u>	00
	TOTAL	\$	764.00

Attached is our check in the amount of \$764.00 to cover the filing fee.

If any discrepancies in the calculated fee, the Commissioner is hereby authorized to charge any and all fees which may be required, or credit any overpayment to our Deposit Account No. 501032. A duplicate copy of this sheet is enclosed.

Y. FUJII et al. Rule 1.53 Divisional of 09/333,521 NZK-128-1

As requested by preliminary amendment, amend the specification on page 1 by inserting prior to "BACKGROUND OF THE INVENTION" the sentence: --This is a divisional of application serial no. 09/333,521 filed June 15, 1999, which claims priority of Japanese application 185,708/1998 filed June 15, 1998.--

It is hereby requested that the compliant computer readable "Sequence Listing" filed via certificate of mailing December 20, 1999, by Preliminary Amendment and Compliance With Sequence Rules 37 C.F.R. 1.821-1.825 and already on file in parent application serial no. 09/333,521 filed June 15, 1999, be used in the above-identified divisional application. The paper copy of the "Sequence Listing" filed herewith is identical to the computer readable copy filed with the Preliminary Amendment and Compliance With Sequence Rules 37 C.F.R. 1.821-1.825, filed December 20, 1999 via certificate of mailing, in parent application serial no. 09/333,521.

Filed concurrently herewith is a Letter Regarding Sequence Listing in Parent Application Serial No. 09/333,521 Under 37 C.F.R. §1.821(e) which refers to the parent application Serial No. 09/333,521 and identifies the compliant computer readable sequence listing filed in the parent application Serial No. 09/333,521.

The parent application is assigned to Nippon Zoki Pharmaceutical Co., Ltd. by virtue of an assignment recorded at Reel 010203, Frame 0313, on August 31, 1999.